Fortrea 与 Omico 携手，推进生物标志物导向的肿瘤药物开发

Fortrea, a leading global contract research organization, has partnered with Omico, Australia's precision oncology screening institution, to accelerate biomarker-driven cancer clinical trials. The collaboration combines Fortrea's oncology trial expertise with Omico's PrOSPeCT program—Australia's largest cancer genomics initiative—to improve patient matching, research center selection, and recruitment efficiency for precision oncology studies.